TG Therapeutics, Inc. (NASDAQ:TGTX) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, President, and Chief Executive Officer Adam Waldman - Chief Commercialization Officer Sean Power - Chief Financial Officer Conference Call Participants Edward White - H.C. Wainright Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Eric Joseph - JPMorgan Prakhar Agrawal - Cantor Fitzgerald Mat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-3898269 (State or other jur ...

TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2023 Earnings Call Transcript August 1, 2023 8:30 AM ET Company Participants Jenna Bosco - Senior Vice President of Corporate Communications Michael Weiss - Chairman, CEO and President Adam Waldman - Chief Commercialization Officer Sean Power - CFO, Corporate Secretary and Treasurer Conference Call Participants Eric Joseph - JP Morgan Ed White - H.C. Wainwright Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Michael DiFiore - Evercore Prakhar Agrawal - Cant ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-3898269 (State or other ju ...

TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2023 Earnings Conference Call May 1, 2023 8:30 AM ET Company Participants Mike Weiss - Chairman & CEO Adam Waldman - CCO Sean Power - CFO Jenna Bosco - IR Conference Call Participants Eric Joseph - JPMorgan Ed White - H. C. Wainwright Prakhar Agrawal - Cantor Fitzgerald Matt Kaplan - Ladenburg Thalmann Mayank Mamtani - B. Riley Securities Josh Schimmer - Evercore ISI Operator Greetings, and welcome to the TG Therapeutics First Quarter 2023 Earnings Call. At this time, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022. OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number 1-32639 TG THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 36-3898269 (Stat ...

TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Jenna Bosco – Investor Relations Michael Weiss – Chairman and Chief Executive Officer Adam Waldman – Chief Commercialization Officer Sean Power – Chief Financial Officer Conference Call Participants Josh Schimmer – Evercore ISI Ed White – H. C. Wainwright Prakhar Agrawal – Cantor Fitzgerald Sahil Kazmi – B. Riley Securities Operator Greetings, and welcome to the TG Therapeutics Fourth Quart ...

J.P. Morgan Virtual 2022 Healthcare Conference January 2022 Forward Looking Safe Harbor Statement 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates", "expects", "plans", "believes", "intends", and similar words or phrases. Such statements involve risks and uncertainties that could cause TG Therapeutics' actual results to d ...

TG Therapeutics ULTIMATE I & II Data Preview Call April 2021 Forward-Looking Safe Harbor Statement ▪ This is presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the Company's current beliefs, expectations and assumptions. These statements include but are not limited to statements regarding the future of the Company's business, our future plans and strategies, clinical trial results, and regulatory filings and approvals. T ...

J.P. Morgan 39th Annual Healthcare Conference January 2021 Forward Looking Safe Harbor Statement 2 | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...